Table 6 New clinical studies evaluating cancer therapeutics for nasopharyngeal cancer patients

Axitinib

NCT04562441

Recruiting

II

n.a

Axitinib + avelumab

R/M NPC

Camerelizumab

NCT04944914

Recruiting

III

Camrelizumab

Camrelizumab + SBRT

Metastatic NPC

NCT03707509

Ongoing

III

Placebos + gemcitabine + cisplatin

Camrelizumab + gemcitabine + cisplatin

R/M NPC chemo-naïve

NCT05011227

Recruiting

II

n.a

Camrelizumab + chemotherapy + endoscopic surgery

Recurrent NPC

NCT04586088

Recruiting

II

n.a

Camrelizumab + apatinib

R/M NPC

NCT04453826

Recruiting

III

IC (gemcitabine + cisplatin) + CCRT (cisplatin + IMRT)

Camrelizumab + IC (gemcitabine + cisplatin) + CCRT (cisplatin + IMRT)

High risk NPC

NCT04782765

Recruiting

II

n.a

IC (camrelizumab + cisplatin) + CCRT + maintenance therapy (camrelizumab)

NPC with no distant metastasis

NCT03427827

Recruiting

III

Chemoradiotherapy + best supportive care

Chemoradiotherapy + camerelizumab

Locoregionally advanced NPC

Capecitabine

NCT02958111

Ongoing

III

No intervention

capecitabine

Locoregionally advanced NPC

NCT02973386

Recruiting

III

CCRT (IMRT + cisplatin)

CCRT (IMRT + cisplatin) + capecitabine

Locally advanced high risk NPC

NCT04220528

Recruiting

II

n.a

IC (gemcitabine) + CCRT (IMRT + nidapatin) + capecitabine/teggio

N3 NPC

Cetuximab

NCT02633176

Recruiting

III

IC (cisplatin + docetaxel) + CCRT (cisplatin) + maintenance therapy (capecitabine)

IC (cetuximab + cisplatin + docetaxel) + CCRT (cetuximab + cisplatin) + maintenance therapy (capecitabine)

Untreated metastatic NPC

Endostar

NCT02636231

Ongoing

II

IMRT

Endostar + IMRT

Locally recurrent NPC

Nimotuzumab

NCT03666221

Recruiting

II

n.a

Nimotuzumab + IMRT

Recurrent NPC

NCT04456322

Recruiting

III

IC (paclitaxel) + CCRT (cisplatin + IMRT)

IC (paclitaxel) + CCRT (nimotuzumab + RT)

Locoregionally advanced low risk NPC

NCT04223024

Ongoing

II

IC (paclitaxel) + CCRT (cisplatin + IMRT)

IC (paclitaxel) + CCRT (cisplatin + IMRT + nimotuzumab)

Advanced high risk NPC

NCT03915132

Recruiting

II

n.a

Nimotuzumab + VMAT (IMRT)

Elderly NPC

NCT03708822

Recruiting

II

n.a

Docetaxel + cisplatin + nimotuzumab

R/M NPC

NCT03837808

Recruiting

III

CCRT (IMRT + cisplatin)

IMRT + concurrent nimotuzumab

Stage II and III NPC

Nivolumab

NCT03097939

Recruiting

II

n.a

Nivolumab + ipilimumab

EBV-driven NPC

NCT03267498

Recruiting

II

n.a

Nivolumab + CCRT (cisplatin)

Stage II–IVB NPC

Pembrolizumab

NCT03734809

Ongoing

II

n.a

IC (pembrolizumab + gemcitabine + cisplatin) + CCRT (cisplatin + pembrolizumab) + maintenance therapy (pembrolizumab)

Untreated stage IVA NPC

NCT02538510

Ongoing

I, II

n.a

Pembrolizumab + vorinostat

R/M NPC

NCT03849469

Ongoing

I

XmAb22841

XmAb22841 + pembrolizumab

Advanced NPC

NCT03674567

Recruiting

I, II

FLX475

FLX475 + pembrolizumab

Advanced NPC

Proton therapy

NCT04870840

Recruiting

I

n.a

Image-guided hyper-fractioned proton therapy

Locally Advanced NPC

Toripalimab

NCT04398056

Ongoing

II

n.a

Chemoradiotherapy (fluorouracil + cisplatin + IMRT) + toripalimab

De novo metastatic NPC

NCT04376866

Recruiting

III

CCRT (cisplatin + IMRT)

CCRT (toripalimab + cisplatin + IMRT) + toripalimab

Locoregionally recurrent NPC

NCT04517214

Recruiting

II

Gemcitabine + cisplatin + IMRT + maintenance therapy (capecitabine)

Toripalimab + gemcitabine + cisplatin + IMRT + maintenance therapy (capecitabine + toripalimab)

Metastatic NPC

NCT04992988

Recruiting

II

n.a

Toripalimab + CCRT (cisplatin)

Locoregionally recurrent NPC

NCT04778956

Recruiting

III

Salvage surgery

Salvage surgery + toripalimab

Resectable locally recurrent NPC

NCT03925090

Recruiting

II

CCRT (cisplatin)

CCRT (cisplatin + IMRT + toripalimab) + toripalimab

Locoregionally advanced high risk NPC

NCT04405622

Ongoing

II

n.a

Toripalimab + gemcitabine + maintenance therapy (toripalimab)

R/M NPC

NCT04453813

Recruiting

III

CCRT (cisplatin + IMRT)

CCRT (toripalimab + cisplatin + IMRT) + toripalimab

Unresectable locally recurrent NPC

NCT03854838

Ongoing

II

n.a

IMRT + toripalimab

Unresectable locally recurrent NPC

NCT02915432

Ongoing

I, II

n.a

First line chemotherapy + toripalimab

Advanced NPC

NCT03907826

Recruiting

III

Chemoradiotherapy (gemcitabine + cisplatin + IMRT)

Toripalimab + chemoradiotherapy (gemcitabine + cisplatin + IMRT)

Recurrent NPC

Toripalimab

NCT03930498

Recruiting

II

n.a

Toripalimab + chemoradiotherapy (gemcitabine + cisplatin + IMRT)

Recurrent high risk NPC

NCT03474640

Ongoing

I

n.a

Toripalimab

Advanced NPC